Protein detail
PDE3A
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A (EC 3.1.4.17) (Cyclic GMP-inhibited phosphodiesterase A) (CGI-PDE A) (cGMP-inhibited cAMP phosphodiesterase) (cGI-PDE)
Entry name PDE3A | UniProt ID | EVMP score 0.50 |
Frequency 1 | Transmembrane count 6 | Protein classification Disease related genesEnzymesFDA approved drug targetsHuman disease related genesMetabolic proteinsPlasma proteinsPredicted membrane proteins |
EVMP score: annotation confidence score.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40
Basic Information
Protein Names
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A (EC 3.1.4.17) (Cyclic GMP-inhibited phosphodiesterase A) (CGI-PDE A) (cGMP-inhibited cAMP phosphodiesterase) (cGI-PDE)
Protein Class
Disease related genesEnzymesFDA approved drug targetsHuman disease related genesMetabolic proteinsPlasma proteinsPredicted membrane proteins
Protein Function
- Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system
- Enzymes
- ENZYME proteins:Hydrolases
- Disease related genes
- FDA approved drug targets:Small molecule drugs
Transmembrane
61..81; Helical; 130..150; Helical; 160..180; Helical; 185..205; Helical; 210..230; Helical; 232..252; Helical
Transmembrane Count
6
Ensembl
Entrez Gene Symbol
Gene Synonym
CGI-PDE
Gene Description
Phosphodiesterase 3A
Chromosome
12
Position
20368537-20688583
Frequency
1
EVMP Score
0.50
Fluorescence & Localization
Function & Pathway
Protein Function
- Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system
- Enzymes
- ENZYME proteins:Hydrolases
- Disease related genes
- FDA approved drug targets:Small molecule drugs
Cellular Component
Molecular Function
- GO:0004114 3',5'-cyclic-nucleotide phosphodiesterase activity
- GO:0004115 3',5'-cyclic-AMP phosphodiesterase activity
- GO:0004118 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity
- GO:0004119 3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity
- GO:0005515 protein binding
- GO:0030284 nuclear estrogen receptor activity
- GO:0046872 metal ion binding
- GO:0047555 3',5'-cyclic-GMP phosphodiesterase activity
- GO:0099130 estrogen binding
Biological Process
KEGG
Mediation Categories
Clinical-translation mediationReceptor-signaling mediation
Relations & Evidence
Enzyme-Mediated Modification
13 records.
| Substrate Gene Symbol | Enzyme Gene Symbol | Enzyme UniProt ID | Residue Type | Residue Offset | Modification | Database | References |
|---|---|---|---|---|---|---|---|
| PDE3A | PRKACA | P17612 | S | 312 | phosphorylation | phosphoELM_MIMPPhosphoSite_MIMPMIMPHPRD_MIMPSIGNORProtMapperSIGNOR_ProtMapperPhosphoSitePhosphoSite_ProtMapper | SIGNOR:16153182ProtMapper:16153182 |
| PDE3A | PRKACA | P17612 | S | 428 | phosphorylation | phosphoELM_MIMPPhosphoSite_MIMPMIMPHPRD_MIMPProtMapperPhosphoSitePhosphoSite_ProtMapper | |
| PDE3A | PRKACA | P17612 | S | 438 | phosphorylation | PhosphoSite | |
| PDE3A | PRKCA | P17252 | S | 438 | phosphorylation | PhosphoSite_MIMPMIMPSIGNORProtMapperSIGNOR_ProtMapperPhosphoSitePhosphoSite_ProtMapper | ProtMapper:19261611SIGNOR:19261611 |
| PDE3A | PRKCA | P17252 | S | 428 | phosphorylation | phosphoELM_MIMPPhosphoSite_MIMPMIMPHPRD_MIMPSIGNORProtMapperSIGNOR_ProtMapperPhosphoSitePhosphoSite_ProtMapper | ProtMapper:19261611SIGNOR:19261611 |
| PDE3A | PRKCA | P17252 | S | 492 | phosphorylation | PhosphoSite_MIMPMIMPHPRD_MIMPSIGNORProtMapperSIGNOR_ProtMapperPhosphoSitePhosphoSite_ProtMapper | ProtMapper:19261611SIGNOR:19261611 |
| PDE3A | PRKCA | P17252 | S | 312 | phosphorylation | phosphoELM_MIMPPhosphoSite_MIMPMIMPHPRD_MIMPSIGNORProtMapperSIGNOR_ProtMapperPhosphoSitePhosphoSite_ProtMapper | ProtMapper:19261611SIGNOR:19261611 |
| PDE3A | PRKCA | P17252 | S | 465 | phosphorylation | PhosphoSite_MIMPMIMPSIGNORProtMapperSIGNOR_ProtMapperPhosphoSitePhosphoSite_ProtMapper | ProtMapper:19261611SIGNOR:19261611 |
| PDE3A | PRKCA | P17252 | S | 293 | phosphorylation | PhosphoSitePhosphoSite_ProtMapperProtMapper | |
| PDE3A | PRKCA | P17252 | S | 292 | phosphorylation | PhosphoSitePhosphoSite_ProtMapperProtMapper |
Page 1 of 2Next
Ligand-Receptor Signaling
14 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| transmembrane | transmembrane | Ramilowski_location | No | No | No | No | No |
| transmembrane | transmembrane | OmniPath | No | No | No | No | No |
| receptor | receptor | scConnect | No | Yes | No | No | No |
| transmembrane | transmembrane_predicted | Phobius | No | No | No | No | No |
Page 2 of 2Previous
Regulatory Interaction Network
3 records.
| Source Protein Symbol | Source UniProt ID | Target Protein Symbol | Target UniProt ID | Is Directed | Is Stimulation | Is Inhibition | Database | References |
|---|---|---|---|---|---|---|---|---|
| KAPCA | P17612 | PDE3A | Q14432 | Yes | Yes | No | WangphosphoELM_MIMPPhosphoSite_MIMPMIMPHPRD_MIMPPhosphoSite_norefSIGNORiPTMnetProtMapperCui2007CA1SIGNOR_ProtMapperPhosphoSite_ProtMapper | CA1:2839485SIGNOR:16153182ProtMapper:16153182 |
| KPCA | P17252 | PDE3A | Q14432 | Yes | Yes | No | phosphoELM_MIMPPhosphoSite_MIMPMIMPHPRD_MIMPPhosphoSite_norefSIGNORiPTMnetProtMapperSIGNOR_ProtMapperPhosphoSitePhosphoSite_ProtMapper | ProtMapper:19261611SIGNOR:19261611PhosphoSite:25593322PhosphoSite:24248367PhosphoSite:16153182 |
| PDE3A | Q14432 | AT2A2 | P16615 | Yes | No | Yes | SIGNOR | SIGNOR:25593322 |
Protein Complex Composition
Isolation & Detection Technology
1 record.
| EV Isolation Method | Detection Method | Number of References | References |
|---|---|---|---|
| Differential UltracentrifugationSize Exclusion Chromatography | Mass spectrometry | 1 | 36573687 |
Sequence, Structure & Domains
Sequences
Length
1,141
Mass
124,979
Sequence
MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ
3D Structural Models
Turn
705..707; 836..839; 859..861; 885..888
Helix
680..682; 683..686; 687..690; 696..703; 710..721; 724..727; 732..744; 754..769; 817..819; 823..835; 845..850; 854..858; 864..879; 881..883; 891..906; 910..912; 913..925; 935..950; 953..955; 958..981; 997..1007; 1009..1018; 1074..1091
Beta Strand
675..678; 691..693; 750..753; 812..815; 926..928; 932..934; 992..994; 1025..1027; 1070..1072
3D Structure
Electron microscopy (5); X-ray crystallography (4)
Domain & Motif Annotations
Compositional Bias
436..448; Low complexity; 465..482; Polar residues; 608..637; Polar residues; 1029..1056; Acidic residues; 1100..1113; Polar residues; 1125..1141; Basic and acidic residues
Domain (FT)
674..1093; PDEase
Region
1..42; Disordered; 436..482; Disordered; 590..640; Disordered; 669..1141; Interaction with SLFN12; 1023..1062; Disordered; 1100..1141; Disordered
Protein Families
- Cyclic nucleotide phosphodiesterase family
- PDE3 subfamily
Sequence Similarities
Belongs to the cyclic nucleotide phosphodiesterase family. PDE3 subfamily.
Clinical Relevance
Disease Involvement
Disease variantFDA approved drug targets
Biomarker
Approved; Discontinued in Phase 1
Drug Targets
FDA approved drug targets
Drugs